Altimmune (NASDAQ:ALT) Issues Quarterly Earnings Results

Altimmune (NASDAQ:ALT) posted its quarterly earnings data on Wednesday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07, FiscalAI reports. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.

Here are the key takeaways from Altimmune’s conference call:

• Altimmune said it raised $225 million in an oversubscribed April offering, bringing pro forma cash to about $535 million and funding the company through the expected 2029 Phase III MASH 52-week data readout.
• The company said its global Phase III MASH study, PERFORMA, is on track to start in the second half of 2026, with the protocol finalized and aligned with both the FDA and EMA.
• Management emphasized pemvidutide’s potential differentiation in MASH, pointing to a favorable tolerability profile, simple titration, sustained weight loss, and possible preservation of lean muscle mass versus some competing GLP-1-based therapies.
• Altimmune said the 48-week Phase II IMPACT results will be presented orally at EASL, including additional fibrosis analysis and other biomarker data, which the company said should reinforce interest in the program.
• Beyond MASH, Altimmune remains on track to report Phase II AUD top-line data next quarter and expects to complete enrollment in the ALD RESTORE trial in the third quarter of 2026.

Altimmune Price Performance

ALT stock traded down $0.06 on Wednesday, reaching $3.02. The company had a trading volume of 3,577,030 shares, compared to its average volume of 4,538,451. Altimmune has a 1 year low of $2.56 and a 1 year high of $7.73. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55. The company’s fifty day moving average is $3.34 and its 200 day moving average is $4.12. The company has a market cap of $392.90 million, a P/E ratio of -2.99 and a beta of 0.18.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ALT. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Friday, March 27th. HC Wainwright boosted their target price on Altimmune from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, March 16th. B. Riley Financial dropped their target price on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Truist Financial began coverage on Altimmune in a research report on Wednesday, March 18th. They set a “buy” rating and a $12.00 target price on the stock. Finally, Wall Street Zen cut Altimmune from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Altimmune currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Insider Transactions at Altimmune

In related news, CEO Jerome Benedict Durso bought 20,000 shares of Altimmune stock in a transaction that occurred on Friday, March 6th. The shares were purchased at an average price of $3.54 per share, with a total value of $70,800.00. Following the purchase, the chief executive officer owned 32,500 shares in the company, valued at $115,050. This represents a 160.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently bought and sold shares of the stock. Arax Advisory Partners lifted its stake in Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after buying an additional 4,076 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in Altimmune in the 1st quarter valued at approximately $50,000. Victory Capital Management Inc. purchased a new stake in Altimmune in the 3rd quarter valued at approximately $38,000. BNP Paribas Financial Markets lifted its stake in shares of Altimmune by 108.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock worth $39,000 after purchasing an additional 5,253 shares during the period. Finally, Quadrature Capital Ltd purchased a new position in shares of Altimmune during the 4th quarter worth $36,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.